This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Endo Pharma to Buy Indevus for $370M

Endo Pharmaceuticals (ENDP - Get Report) announced Monday afternoon that it would buy Indevus Pharmaceuticals (IDEV) for about $370 million.

Under the terms of the merger, approved by the boards of both companies, Endo will acquire Indevus for $370 million, or $4.50per share, in cash, plus up to an extra $267 million, or $3 per share, in cash "payable in the future upon achievement of certain milestones," according to a statement from Indevus.

"We believe Endo's proven commercial capabilities, targeted approach to medical marketing and unique understanding of the changes taking place in health care delivery today will ensure the success of our current and future products," said Dr. Glenn L. Cooper, chairman and chief executive officer of Indevus.

Endo shares closed down $2.03, or 7.8%, at $24.05 Monday, and Indevus shares closed down 5 cents, or 1.6%, at $3.10.

An analyst at Caris & Co cut its rating on Endo to above average from buy Monday morning, saying the company's proposed near-term growth strategy was unclear.

Endo competes in the biotech space with Abbott Labs (ABT - Get Report) and Pfizer (PFE - Get Report). Indevus competes with Allergan (AGN - Get Report), Johnson & Johnson (JNJ - Get Report) and Watson Pharmaceuticals (WPI).
This article was written by a staff member of

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
WPI $85.73 0.00%
ABT $38.85 -0.13%
AGN $218.11 0.72%
ENDP $27.18 0.67%
JNJ $112.75 0.60%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs